Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage. … Read more
Captor Therapeutics S.A. (CTX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.346x
Based on the latest financial reports, Captor Therapeutics S.A. (CTX) has a cash flow conversion efficiency ratio of -0.346x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł-11.51 Million) by net assets (zł33.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Captor Therapeutics S.A. - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Captor Therapeutics S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Captor Therapeutics S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Captor Therapeutics S.A. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Premier American Uranium Inc
PINK:PAUIF
|
-0.513x |
|
Pix Transmissions Limited
NSE:PIXTRANS
|
0.018x |
|
Dexxos Participações S.A
SA:DEXP3
|
0.115x |
|
Acer Cyber Security Inc.
TWO:6690
|
0.183x |
|
Eastern Polymer Group Public Company Limited
BK:EPG
|
0.054x |
|
RUMBLEON CL.B DL-001
F:4Q01
|
N/A |
|
Tri-County Financial Group Inc
OTCQX:TYFG
|
N/A |
|
Globalworth REIT
LSE:GWI
|
0.022x |
Annual Cash Flow Conversion Efficiency for Captor Therapeutics S.A. (2017–2024)
The table below shows the annual cash flow conversion efficiency of Captor Therapeutics S.A. from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | zł64.47 Million | zł-31.88 Million | -0.494x | +34.44% |
| 2023-12-31 | zł69.22 Million | zł-52.20 Million | -0.754x | -216.56% |
| 2022-12-31 | zł96.32 Million | zł-22.95 Million | -0.238x | -3.92% |
| 2021-12-31 | zł124.20 Million | zł-28.47 Million | -0.229x | -138.68% |
| 2020-12-31 | zł-1.00 Million | zł-595.00K | 0.593x | -42.31% |
| 2019-12-31 | zł4.28 Million | zł4.39 Million | 1.027x | +265.41% |
| 2018-12-31 | zł3.43 Million | zł-2.13 Million | -0.621x | -104.27% |
| 2017-12-31 | zł144.00K | zł2.10 Million | 14.563x | -- |